Recently, The Wellness Company unveiled a pioneering human observational study regarding the off-label application of ivermectin and mebendazole for treating cancer, published in the anti-cancer research journal.
Dr. Peter McCullough, who serves as the chief scientific officer at The Wellness Company and co-author of the study, expressed enthusiasm for the findings. He noted that this unique observational analysis indicated a striking clinical efficacy rate of 84% in cancer treatment through the off-label use of these drugs. He suggested that the affordable and safe application of ivermectin and mebendazole could be a significant advance in cancer care.
The anti-cancer research journal, established in 1995, is recognized as a leading international publication in the field of oncology by the International Institute for Anticancer Research.
Nicholas Hulscher from the McCullough Foundation highlighted the importance of such studies, stating that “real-world observational studies are crucial because they accurately reflect the usage of ivermectin and mebendazole in practical scenarios.” This work represents the largest peer-reviewed human study investigating the combination of these drugs in cancer treatment.
84% of cancer patients report clinical benefit
A recent observational analysis revealed a remarkable clinical benefit rate of 84.4% for cancer patients treated with off-label ivermectin and mebendazole. The results suggest that these accessible and inexpensive medications could contribute to significant advancements in cancer treatment. The study involved 197 cancer patients who were administered a combination of ivermectin (25 mg) and mebendazole (250 mg), according to insights from the Wellness Company’s Chief Medical Committee and the McCullough Foundation.
Out of the 122 patients who completed six months of follow-up:
- 84.4% noted clinical benefit (indicating no disease present, tumor reduction, or stable disease)
- 48.4% experienced the most favorable outcomes (witnessing tumor shrinkage or absence of disease)
- 86.9% finished their initial prescription (most side effects were mild)
Cancer remains a leading cause of death globally, and traditional treatments like chemotherapy and radiotherapy often face challenges due to toxicity, high costs, resistance development, and varied long-term efficacy.
Researchers at The Wellness Company pursued this study as both ivermectin and mebendazole showed potential anti-cancer effects in preclinical models. However, despite promising initial data and safe usage in cancer patients, there remains a lack of robust clinical research evaluating the combination of these drugs in oncology.
Dr. McCullough commented, “This study unveils an exciting new avenue by considering ivermectin and mebendazole for various cancer types. Serious scientific exploration of this drug class and its effects on cancer treatment is urgently needed.”
How to access ivermectin and mebendazole
The Wellness Company stands out as the sole provider of a U.S. formulation combining ivermectin and mebendazole in high-dose tablets.
Ivermectin is scientifically supported and recognized with a Nobel Prize, providing targeted treatment for parasitic infections and ensuring effective care for families.
Mebendazole is trusted by healthcare providers for its targeted elimination of intestinal parasites, safeguarding family health with proven efficacy and safety.
The Wellness Company allows individuals to order a 45-day or 90-day supply of Ivermectin + Mebendazole, regarded as a powerful parasite treatment, after completing a simple medical intake form post-checkout. Available for U.S. residents only.
what people are saying about Ivermectin + Mebendazole
I was diagnosed with stage 4 metastatic breast cancer and considered terminal. A recent PET scan revealed no remaining cancer in my body. I believe ivermectin and mebendazole were crucial in this transformation. – Judith M.
After my daughter was diagnosed with uterine cancer and lung nodules, she began treatment with ivermectin/mebendazole two weeks ago. Her recent PET scan showed numerous nodules, but doctors only found a small one suitable for biopsy. We are grateful to the medical professionals here for giving us hope! – Helen
